CRL.Medinet Expands Global Central Laboratory Services to Japan

15-Jan-2004

CRL.Medinet, the global central laboratory network based in Kansas/ USA and the Eurofins subsidiary and co-founder of CRL.Medinet, Analytico Medinet in Breda/ The Netherlands, recently formalized their relationship with SBS Inc. (Tokyo/ Japan), one of the leading clinical trial service providers in Japan.

With this agreement, CRL.Medinet now provides its internationally operating customers from the pharmaceutical industry also in Japan and the neighbouring regions with fully standardised and specialised safety testing services for their global clinical trials. The Japanese drug market is assessed to be the second largest market worldwide.

SBS was established in 1972 as a spin-off from the Tokyo University and provides clinical services to Japan's largest hospitals, medical centres and research laboratories. The SBS laboratory is located near Tokyo and Narita Airport and operates more than 30 local offices throughout Japan.

CRL.Medinet was founded in 1996 in Europe (Breda/ The Netherlands) and the USA (Kansas City, KS). During the past years, the laboratory network for phase I-IV clinical trials testing expanded to Australia (Sydney, 1997), South Africa (Cape town, 1997) and Japan (Tokyo, 2003). The CRL.Medinet laboratory network consists of five fully standardised laboratories using global Standard Operation Procedures (SOP) and global reference ranges. As all CRL.Medinet laboratories, SBS Inc. participates in the same external Quality Assurance and proficiency testing programmes and is accredited to all relevant quality standards (i.e. CAP and ISO15189 TÜV).

"With SBS, CRL.Medinet has won a strong partner for its global network of laboratories", comments Drs. Ir. Wichers, Vice-Chairman of Eurofins Scientific and responsible for the pharmaceutical division. "This partnership is a further step towards achieving the strategic objective to provide our internationally operating clients with global standardised central laboratory services of optimal regional coverage and minimal logistical overhead."

Tim Sotos, the CEO of Clinical Reference Laboratory Inc. and CRL.Medinet Inc, comments, "We are proud to have SBS in the CRL.Medinet group. Their quality, culture and values and the profound commitment of their management to our global central laboratory service, will enable the CRL.Medinet Group to continue to provide unsurpassed service to the global pharmaceutical industry."

Kazuo Bo, CEO of SBS states: "By extending our clinical trial services to a global level we emphasise our commitment to the highest quality level in laboratory results; SBS was the first laboratory in Japan to receive the international standard ISO 15189 for clinical laboratory services".

https://www.bionity.com/en/news/33545/crl-medinet-expands-global-central-laboratory-services-to-japan.html